CYTK News and Press, Cytokinetics Incorporated From 05/08/24

2024-05-08 16:00:49 ET More on Cytokinetics Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics names Sung Lee as CFO Cyt...

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Opened Enrollment to CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population with Obstr...

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM ( C linical E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of ...

Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWS...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 17:20:38 ET More on Cytokinetics Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics names Sung Lee as CFO Cyt...

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results from SEQUOIA-...

2024-04-26 16:32:49 ET More on Cytokinetics Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics releases more data on hypertrophic cardiomyopathy drug aficamten Cytokinetics gains amid renewed tak...

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a con...

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10...